ALISKIREN 300 MG TABLET
For 30 tablets
Pharmacies pay
$175.75 filed
30 × $5.85836 per EA
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D paid
$130.69 filed
30 × $4.35618 per EA, Part D average
Medicare's price is not your price.
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
The spread
0.74× estimated
Medicare paid 26% less than pharmacies pay.
Part D averages every strength and form sold under “Aliskiren” / “Aliskiren Hemifumarate” into one figure, so it is not specific to this NDC.
OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)
Cost-plus estimate
$207.11 estimated
$175.75 + $26.36 (15%) + $5.00 fee per fill = $207.11
This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out
OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)
Open the interactive card Change the quantity, type what you were charged, and see every record in full.
What it is
ALISKIREN 300 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as “aliskiren” and “aliskiren hemifumarate”, as its NDCs’ listings variously write the nonproprietary name.
FDA gives its dosage form as tablet, film coated and its route as oral.
Its labelers, the companies named on the label, are Par Health USA, LLC and Prasco Laboratories.
FDA’s Established Pharmacologic Class for it is Renin Inhibitor.
The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).
NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.
What pharmacies pay
Pharmacies pay $175.75 for 30 tablets (30 × $5.85836 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.
NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 6, the CMS Covered Outpatient Drug Product File S/I/N drug category was not applied when grouping drugs for the calculation.
What NADAC measures · Why 30 tablets · NADAC explanation codes
All 2 NDCs
- 49884-0425-11 · Par Health USA, LLC · $5.85836 per EA · eff. 2026-09-23 filed
- 66993-0142-30 · Prasco Laboratories · $5.85836 per EA · eff. 2026-09-23 filed
Other strengths, forms and brands
2 other products in the NADAC file share an FDA nonproprietary name with ALISKIREN 300 MG TABLET.
| Product | Pharmacies pay per unit | Medicare per unit |
|---|---|---|
| ALISKIREN 150 MG TABLET | $3.93745 per EA filed | $4.35618 per EA filed |
| ALISKIREN 300 MG TABLET this page | $5.85836 per EA filed | $4.35618 per EA filed |
| TEKTURNA 300 MG TABLET | $15.09446 per EA filed | $11.32191 per EA filed |
Part D is one average per brand and generic name, over every strength and form.
CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-01-06, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17
Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18
What Medicare paid
Medicare Part D paid $130.69 for 30 tablets, at an average of $4.35618 per EA in 2024 (2024-01-01 to 2024-12-31) for “Aliskiren” and “Aliskiren Hemifumarate”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).
That average covers 29,887 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.
1 of the product’s 2 NDCs have this Medicare figure; the other 1 do not, and the interactive card says why for each.
Medicare's price is not your price.
What Part D spending measures · Which Medicare figure OpenBill compares · How the spread is worked out
What to ask at the counter
None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.
- What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
- If you have Medicare Part D: what is my plan’s copay or coinsurance for it? The Part D average on this page is not what you pay.
- These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.
Questions
- Why is the comparison with Medicare for ALISKIREN 300 MG TABLET labelled estimated?
- Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Aliskiren / Aliskiren Hemifumarate: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name.